Document:

Execution
Version

 

Certain
identified information has been excluded from the document because it is both (i) not material and (ii) would be competitively
harmful if publicly disclosed.

 

Services
Agreement

 

This
Services Agreement (“Agreement”), dated as of October 10, 2019, is by and between OncoSec Medical Incorporated,
a Nevada corporation (“OncoSec”), and Sirtex Medical US Holdings, Inc., a Delaware corporation (“Sirtex”)
(each, a “Party” and, collectively, the “Parties”).

 

A.
OncoSec develops device/drug combination therapies as described below.

 

B.
The Parties are entering into the Stock Purchase Agreement (as defined below), pursuant to which Sirtex will invest into, and
obtain partial ownership of, OncoSec.

 

C.
OncoSec desires to obtain, and Sirtex desires to provide, certain Services (as defined below) pursuant to the terms set forth
in this Agreement, and in exchange OncoSec is willing to pay certain Royalties (as defined below) on the future sale of the Products.

 

NOW,
THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

 

	1.	Definitions.

 

Unless
otherwise specifically provided herein, the following terms shall have the meanings set forth in this Section 1 and capitalized
terms used but not otherwise defined herein shall have the respective meanings ascribed thereto in the Stock Purchase Agreement.
For the avoidance of doubt, such meanings shall, to the extent used herein, survive any termination or expiration of the Stock
Purchase Agreement.

 

	1.1.	“Adverse
                                         Ruling” has the meaning set forth in Section 5.2.

 

	1.2.	“Affiliate”
                                         means any company, partnership, joint venture or other entity, which directly or indirectly
                                         controls, is controlled by or is under common control with a respective named Party.
                                         Control shall mean the possession of more than fifty percent (50%) of the voting stock
                                         or the power to control the management and policies of the controlled entity, whether
                                         through the ownership of voting securities, by contract, or otherwise.

 

	1.3.	“Agreement”
                                         has the meaning set forth in the preamble hereto.

 

	1.4.	“Audit”
                                         has the meaning set forth in Section 3.7.

 

	1.5.	“Breaching
                                         Party” has the meaning set forth in Section 5.2.

 

	1.6.	“Calendar
                                         Half” means the respective periods of six consecutive calendar months as follows:
                                         January 1 to June 30 or July 1 to December 31, except that the first Calendar Half of
                                         the Term shall commence on the Effective Date and end on the day immediately prior to
                                         the first to occur of January 1 or July 1 after the Effective Date, and the last Calendar
                                         Half of the Term shall end on the last day of the Term.

 

    	 	 	 

    	 

    

 

	1.7.	“Calendar
                                         Year” means the respective periods of twelve consecutive calendar months ending
                                         on December 31, except that (a) the first Calendar Year under this Agreement shall commence
                                         on the Effective Date and end on the first December 31 to occur after the Effective Date
                                         and (b) the last Calendar Year under this Agreement shall commence on the last January
                                         1 to occur prior to the end of the Term and end at the end of the Term.

 

	1.8.	“Confidential
                                         Information” has the meaning set forth in Section 9.1.

 

	1.9.	“Copyrights
                                         and Trademarks” has the meaning set forth in Section 8.

 

	1.10.	“Deliverables”
                                         has the meaning set forth in Section 8.

 

	1.11.	“Effective
                                         Date” has the meaning set forth in Section 5.1.

 

	1.12.	“Indemnification
                                         Claim Notice” has the meaning set forth in Section 7.3(a).

 

	1.13.	“Indemnified
                                         Party” has the meaning set forth in Section 7.3(a).

 

	1.14.	“Joint
                                         Steering Committee” or “JSC” means the committee established
                                         as set forth in Section 4.1.

 

	1.15.	“Late
                                         Payment Notice” has the meaning set forth in Section 3.4.

 

	1.16.	“Losses”
                                         has the meaning set forth in Section 7.1.

 

	1.17.	“Material
                                         Breach” has the meaning set forth in Section 5.2.

 

	1.18.	“Material
                                         Breach Notice” has the meaning set forth in Section 5.2.

 

	1.19.	“Net
                                         Sales” means the total amount billed or invoiced on sales of the Products by
                                         OncoSec or its Affiliates to any Third Party, less the following deductions:

 

		(a)	trade,
                                         cash and quantity discounts;

		(b)	price
                                         reductions or rebates, retroactive or otherwise, imposed by, negotiated with or otherwise
                                         paid to Governmental Authorities;

		(c)	taxes
                                         on sales (such as sales, value added, or use taxes) to the extent added to the sale price
                                         and set forth separately as such in the total amount invoiced;

		(d)	amounts
                                         repaid or credited by reason of rejections, defects, return goods allowance, recalls
                                         or returns, or because of retroactive price reductions, including rebates or wholesaler
                                         charge backs;

		(e)	the
                                         portion of administrative fees paid during the relevant time period to group purchasing
                                         organizations or pharmaceutical benefit managers relating to the applicable Product;

		(f)	any
                                         consideration actually paid or payable by OncoSec or its Affiliates for the procurement
                                         of any generator that is included in the applicable Product;

		(g)	any
                                         invoiced amounts which are not collected by OncoSec or its Affiliates, including bad
                                         debts;

		(h)	freight,
                                         insurance, and other transportation charges to the extent added to the sale price and
                                         set forth separately as such in the total amount invoiced, as well as any fees for services
                                         provided by wholesalers and warehousing chains related to the distribution of the applicable
                                         Product; and

 

    	 	2	 

    	 

    

 

		(i)	any
                                         other similar and customary deductions that are consistent with generally accepted accounting
                                         principles applicable for the applicable jurisdiction.

 

In
each case the following provisions apply: Net Sales shall not include transfers or dispositions for charitable, promotional, pre-clinical,
clinical, regulatory, or governmental purposes. For clarity, Net Sales shall not include sales between or among OncoSec or its
Affiliates. Subject to the above, Net Sales shall be calculated in accordance with the standard internal policies and procedures
of OncoSec or its Affiliates, which must be in accordance with applicable generally accepted accounting principles in the applicable
jurisdiction.

 

	1.20.	“Non-Breaching
                                         Party” has the meaning set forth in Section 5.2.

 

	1.21.	“OncoSec”
                                         has the meaning set forth in the preamble hereto.

 

	1.22.	“Party”
                                         and “Parties” have the meanings set forth in the preamble hereto.

 

	1.23.	“Payment
                                         Records” has the meaning set forth in Section 3.6.

 

	1.24.	“Products”
                                         means TAVO and Visceral Lesion Applicator (VLA) products and their accompanying generators,
                                         and any products (including, for clarity, combination products) incorporating or including
                                         such products and their accompanying generators.

 

	1.25.	“Royalty”
                                         has the meaning set forth in Section 3.1.

 

	1.26.	“Services”
                                         has the meaning set forth in Section 2.1.

 

	1.27.	“Sirtex”
                                         has the meaning set forth in the preamble hereto.

 

	1.28.	“Sirtex
                                         Personnel” has the meaning set forth in Section 8.

 

	1.29.	“Stock
                                         Purchase Agreement” means that certain Stock Purchase Agreement, dated as of
                                         the date hereof, by and between OncoSec and Sirtex.

 

	1.30.	“Term”
                                         has the meaning set forth in Section 5.1.

 

	1.31.	“Territory”
                                         means all countries other than the following countries: Greater China (Mainland,
                                         Hong Kong, Macau, Taiwan), Armenia, Azerbaijan, Bahrain, Bangladesh, Bhutan, Brunei,
                                         Burma, Cambodia, East Timor, Georgia, India, Indonesia, Jordan, Kazakhstan, Kuwait, Kyrgyzstan,
                                         Laos, Malaysia, Mongolia, Nepal, Oman, Pakistan, Papua New Guinea, Philippines, Qatar,
                                         Saudi Arabia, Singapore, South Korea, Sri Lanka, Tajikistan, Thailand, Turkmenistan,
                                         United Arab Emirates, Uzbekistan and Vietnam.

 

	1.32.	“Third
                                         Party” means any entity other than the Parties and their Affiliates.

 

	1.33.	“Third
                                         Party Claims” has the meaning set forth in Section 7.1.

 

    	 	3	 

    	 

    

 

	2.	Services.
	 	 
	2.1.	Services.
                                         From and after the Effective Date, Sirtex shall provide to OncoSec services, in the categories
                                         as described in Exhibit A, in respect of the Products (the “Services”).
                                         The JSC shall agree upon the details of the Services from time to time during the Term.
                                         Sirtex shall provide the Services (a) in accordance with the terms and subject to the
                                         conditions set forth in this Agreement; (b) using personnel of required skill, experience,
                                         licenses, and qualifications; and (c) in a timely, workmanlike, and professional manner.
                                         Nothing in this Agreement shall be construed to prevent OncoSec from itself performing
                                         or from receiving services from other providers that are similar or identical to the
                                         Services.

 

	3.	Royalty
                                         and Payment Obligations.
	 	 
	3.1.	Royalty.
                                         During the Term, OncoSec shall pay to Sirtex a royalty of [ * ] of Net Sales of
                                         all Products in the Territory (the “Royalty”).
 

 

	3.2.	Reporting.
                                         OncoSec shall submit to Sirtex within [ * ] days after the end of each Calendar
                                         Half, an accurate, complete, itemized report setting forth for such year (together with
                                         cumulative year over year sales) at least the following information:

 

		(a)	the
                                         quantity of Net Sales for the applicable Calendar Half on a country-by-country basis;
                                         and

		(b)	the
                                         amount of Royalty due thereon, or, if no Royalties are due to Sirtex for any reporting
                                         period, a statement that no Royalties are due.

 

	3.3.	Payments;
                                         Payment Method; Currency Conversion. Together with the Calendar Half-by-Calendar
                                         Half report described above, OncoSec shall pay in full all Royalties due for the applicable
                                         Calendar Half. All payments to be made hereunder shall be made in U.S. Dollars in immediately
                                         available funds via either a bank wire transfer, an ACH (automated clearing house) mechanism,
                                         or any other means of electronic funds transfer, at OncoSec’s election, to a bank
                                         account specified by Sirtex in a notice at least [ * ] Business Days before the
                                         applicable payment is due. For the purposes of determining the amount of any payments
                                         due hereunder for the relevant Calendar Half, the amount of Net Sales in any foreign
                                         currency shall be converted into U.S. Dollars in accordance with the prevailing rates
                                         of exchange for the relevant month for converting such first currency into such other
                                         currency used by OncoSec’s internal accounting systems.

 

	3.4.	Interest
                                         on Late Payments. If a Party shall fail to make a timely payment pursuant to the
                                         terms of this Agreement, the other Party shall provide written notice of such failure
                                         to the non-paying Party (a “Late Payment Notice”), and interest shall
                                         accrue on the past due amount starting on the date of the Late Payment Notice at the
                                         thirty (30) day U.S. Dollar London Interbank Offered Rate effective for the date that
                                         payment was due (as published in the Wall Street Journal), computed for the actual number
                                         of days after the date of the Late Payment Notice that the payment was past due.

 

    	 	4	 

    	 

    

 

	3.5.	Taxes.
                                         All payments required to be paid to Sirtex pursuant to this Agreement shall be made without
                                         deduction or withholding for taxes, except for withholding taxes, value-added taxes and
                                         government surcharges attached to the value-added taxes required to be deducted or withheld
                                         by OncoSec under applicable Law on amounts payable to Sirtex hereunder; provided, however,
                                         that OncoSec shall provide Sirtex with a receipt in respect of any taxes deducted or
                                         withheld and remitted to the applicable Governmental Authority. [ * ]. Sirtex
                                         alone shall be responsible for paying any and all taxes (other than withholding taxes,
                                         value-added taxes and all government surcharges attached to the value-added taxes deducted
                                         and withheld on Sirtex’s behalf by OncoSec in accordance with this Section 3.5)
                                         levied on account of, or measured in whole or in part by reference to, any payments Sirtex
                                         receives. Without limiting the foregoing, the Parties agree to reasonably cooperate with
                                         one another in availing themselves of the benefit of any tax treaty to minimize any applicable
                                         withholding tax with respect to payments hereunder to the extent permitted under applicable
                                         Law.

 

	3.6.	Books
                                         and Records. OncoSec shall keep, and shall require its Affiliates to keep, complete,
                                         accurate records (together with supporting documentation) of Net Sales under this Agreement,
                                         reasonably appropriate to determine the amount of Royalties due to Sirtex hereunder (collectively
                                         “Payment Records”). Payment Records shall be retained for at least
                                         five (5) years following the end of the reporting period to which they relate.

 

	3.7.	Audit.
                                         Sirtex shall have the right, once annually at its own cost and expense, to have an independent,
                                         certified public accounting firm, selected by Sirtex and approved by OncoSec in its reasonable
                                         discretion, review Payment Records in the location(s) where such records are maintained
                                         upon reasonable notice to OncoSec (which shall be no less than twenty (20) days prior
                                         notice) and during regular business hours and under obligations of strict confidence,
                                         for the sole purpose of verifying the basis and accuracy of payments made under this
                                         Agreement within the lesser of (a) the twenty-four (24) month period preceding the date
                                         of the request for review or (b) the period after Sirtex’s most recent audit conducted
                                         under this Section 3.7 (or any other applicable section of this Agreement) (an “Audit”).
                                         The report of such Audit shall be limited to a certificate stating whether any report
                                         made or payment submitted by OncoSec during such period is accurate or inaccurate and
                                         the actual amounts of Net Sales and Royalties due, for such period. OncoSec shall receive
                                         a copy of each such report concurrently with receipt by Sirtex. Should such inspection
                                         lead to the discovery of a discrepancy to Sirtex’s detriment, and only to the extent
                                         that OncoSec agrees with and accepts such conclusion under the Audit, OncoSec shall pay
                                         within thirty (30) Business Days after its receipt from the accounting firm of the certificate,
                                         the amount of the discrepancy plus interest calculated in accordance with this Agreement.
                                         If OncoSec does not agree with the conclusion of such report, the matter shall be referred
                                         to dispute resolution in accordance with Section 10.5. Sirtex shall pay the full cost
                                         of the Audit unless the underpayment discovered by the Audit is greater than [ * ]
                                         percent ([ * ]%) of the amount due for the applicable period covered by the
                                         Audit. Any overpayment by OncoSec revealed by an Audit shall be fully creditable against
                                         future payments to be made to Sirtex hereunder.

 

    	 	5	 

    	 

    

 

	4.	Governance.
	 	 
	4.1.	Joint
                                         Steering Committee. After the Effective Date, the Parties will establish a Joint
                                         Steering Committee, composed of three (3) senior personnel of OncoSec and three (3) senior
                                         personnel of Sirtex. The appointed personnel for each Party, collectively, shall have
                                         a general understanding of development, regulatory and commercialization issues. Within
                                         thirty (30) days following the Effective Date, each Party will designate its initial
                                         members to serve on the JSC and notify the other Party of the dates of availability for
                                         the first meeting of the JSC. Each Party may replace its representatives on the JSC on
                                         written notice to the other Party.

 

	4.2.	JSC
                                         Activities. The JSC will: (a) review and discuss the Services provided under this
                                         Agreement; (b) serve as a forum to keep Sirtex informed of issues related to the development
                                         or commercialization of the Products; (c) review and discuss the proposed commercialization
                                         strategies with respect to the Products; and (d) consider and act upon such other matters
                                         as specified in this Agreement. The JSC will also be responsible for resolving, pursuant
                                         to Section 4.4, any disputes that may arise between the Parties. The JSC also may, at
                                         any time it deems necessary or appropriate, establish additional joint committees and
                                         delegate such of its responsibilities as it determines appropriate to such joint committees.

 

		4.3.	Meetings
                                         of the Joint Steering Committee.

 

		(a)	The
                                         JSC shall meet quarterly during the Term and at such other times as the Parties may agree.
                                         The first meeting of the JSC shall be held as soon as reasonably practicable after the
                                         Effective Date, but in no event later than forty-five (45) days following the Effective
                                         Date. Meetings shall be held at such place or places as are mutually agreed or by teleconference
                                         or videoconference; provided, however, that there shall be at least one face-to-face
                                         meeting per Calendar Year, unless the Parties otherwise agree.

 

		(b)	Each
                                         Party may from time to time invite a reasonable number of participants, in addition to
                                         its representatives, to attend JSC meetings, with the consent of the other Party (which
                                         shall not be unreasonably withheld).

 

		(c)	Sirtex
                                         shall appoint one of its representatives on the JSC to act as chairperson of the JSC.
                                         The chairperson shall set agendas for JSC meetings, provided that the agendas will include
                                         any matter requested by either Party. The chairperson shall be responsible for recording,
                                         preparing and, within a reasonable time, issuing draft minutes of each JSC meeting, which
                                         draft minutes shall be subject to review and approval by all JSC members.

 

	4.4.	Decision
                                         Making. Each Party shall in good faith consult with the other and take such other
                                         Party’s views into account in respect of any matter before the JSC or any other
                                         committee established by the Parties hereunder, it being understood and agreed that the
                                         Parties shall not modify or amend the Services without mutual agreement of the Parties.
                                         In the event of a disagreement among the JSC, the matter shall be referred to the Chief
                                         Executive Officers of each Party who shall, for forty-five (45) days after such referral,
                                         attempt in good faith to resolve such disagreement. If such attempt fails, then the dispute
                                         resolution provisions of Section 10.5 shall apply.

 

    	 	6	 

    	 

    

 

	4.5.	Costs
                                         of Governance. The Parties agree that the costs incurred by each Party in connection
                                         with its participation at any meetings under this Section 4 shall be borne solely by
                                         such Party.

 

	5.	Term
                                         and Termination.
	 	 
	5.1.	Term.
                                         This Agreement shall be deemed to have commenced as of the first to occur of (a) the
                                         Closing Date or (b) the termination of the Stock Purchase Agreement by OncoSec other
                                         than pursuant to Section 10.1(a)(iv)(ii) of the Stock Purchase Agreement (the “Effective
                                         Date”) and, unless terminated earlier in accordance with this Section 5, shall
                                         remain in force on a country-by-country and Product-by-Product basis until the later
                                         of (a) the [ * ] anniversary of the first commercial sale of the applicable Product
                                         in the applicable country or (b) the expiration of the last-to-expire patent owned or
                                         controlled by OncoSec that covers the applicable Products in the applicable country (the
                                         “Term”).

 

	5.2.	Termination
                                         for Material Breach. If either Party (the “Non-Breaching Party”)
                                         believes that the other Party (the “Breaching Party”) has materially
                                         breached one or more of its material obligations under this Agreement (a “Material
                                         Breach”), then the Non-Breaching Party may give the Breaching Party notice
                                         of such Material Breach (a “Material Breach Notice”) specifying the
                                         nature of the breach. If the Breaching Party does not dispute that it has committed a
                                         Material Breach, then, if the Breaching Party fails to cure such breach, or fails to
                                         take steps as would be considered reasonable to effectively cure such breach, within
                                         [ * ] days after receipt of the Material Breach Notice, the Non-Breaching Party
                                         may terminate this Agreement upon written notice to the Breaching Party. If the Breaching
                                         Party disputes that it has committed a Material Breach, the dispute shall be resolved
                                         pursuant to Section 10.5. If, as a result of the application of such dispute resolution
                                         procedures, the Breaching Party is determined to have committed a Material Breach (an
                                         “Adverse Ruling”), then, if the Breaching Party fails to complete
                                         the actions specified by the Adverse Ruling to cure such breach within [ * ] days
                                         after such ruling or such longer period as specified in the Adverse Ruling, the Non-Breaching
                                         Party may terminate this Agreement upon written notice to the Breaching Party. The right
                                         of either Party to terminate this Agreement as set forth in this Section 5.2 shall not
                                         be affected in any way by its waiver of, or failure to take action with respect to, any
                                         previous default.

 

	5.3.	Termination
                                         for Convenience. Sirtex may terminate this Agreement in its entirety for any reason
                                         or no reason upon [ * ] days’ prior written notice to OncoSec.

 

    	 	7	 

    	 

    

 

	5.4.	Termination
                                         for Insolvency. This Agreement may be terminated by a Party upon written notice to
                                         the other Party (a) if the other Party shall make an assignment for the benefit of its
                                         creditors, file a petition in bankruptcy, petition or apply to any tribunal for the appointment
                                         of a custodian, receiver or trustee for it or a substantial part of its assets, or shall
                                         commence any proceeding under any bankruptcy, reorganization, readjustment of debt, dissolution
                                         or liquidation law or statute of any jurisdiction, whether now or hereafter in effect;
                                         (b) if there shall have been filed against the other Party any such bona fide petition
                                         or application, or any such proceeding shall have been commenced against it, in which
                                         an order for relief is entered or that remains undismissed or unstayed for a period of
                                         [ * ] days or more; (c) if the other Party by any act or omission shall indicate
                                         its consent to, approval of or acquiescence in any such petition, application or proceeding
                                         or order for relief or the appointment of a custodian, receiver or trustee for it or
                                         any substantial part of its assets, or shall suffer any such custodianship, receivership
                                         or trusteeship to continue undischarged or unstayed for a period of [ * ] days
                                         or more; or (d) anything analogous to any of the foregoing occurs in any applicable jurisdiction.
                                         Termination pursuant to this Section 5.4 shall be effective upon the date specified in
                                         such notice.

 

	5.5.	Effect
                                         of Termination. On any expiration or termination of the entirety of this Agreement,
                                         the receiving Party shall (a) return to the disclosing Party all documents and tangible
                                         materials (and any copies) containing, reflecting, incorporating, or based on the disclosing
                                         Party’s Confidential Information; (b) permanently erase the disclosing Party’s
                                         Confidential Information from its computer systems; and (c) certify in writing to the
                                         disclosing Party that it has complied with the requirements of this Section 5.5. Notwithstanding
                                         the foregoing, the receiving Party will be permitted to retain such Confidential Information
                                         (x) to the extent necessary or useful for purposes of performing any continuing obligations
                                         or exercising any ongoing rights hereunder and, in any event, a single copy of such Confidential
                                         Information for archival purposes and (y) any computer records or files containing such
                                         Confidential Information that have been created solely by such receiving Party’s
                                         automatic archiving and back-up procedures, to the extent created and retained in a manner
                                         consistent with such receiving Party’s standard archiving and back-up procedures,
                                         but not for any other uses or purposes.

 

	5.6.	Survival.
                                         The following Sections of this Agreement will survive the expiration or termination of
                                         this Agreement: 1 (to the extent the definitions in such Section are necessary to construe
                                         the other surviving provisions of this Agreement), 3 (solely in respect of Net Sales
                                         made or Royalties or other payments accrued during the Term), 5.5, 5.6, 6.4, 7, 8, 9
                                         (for the period specified in Section 9.5), and 10.

 

	6.	Warranties;
                                         Disclaimer; Limitation of Liability.
	 	 
	6.1.	Good
                                         Standing. Each Party represents and warrants to the other Party that it is a corporation
                                         duly organized, validly existing and in good standing under the laws of the jurisdiction
                                         of its formation, and has all necessary corporate powers to own, use and transfer its
                                         properties and assets, and to carry on its business as now owned and operated.

 

	6.2.	No
                                         Conflicts. Each Party represents and warrants to the other that (a) the entering
                                         into by such Party of this Agreement and the performance and consummation by such Party
                                         of the matters contemplated hereby does not and shall not violate any (i) agreement with
                                         or obligation to (whether express, implied or by operation of law) any other Person to
                                         which such Party is a party or subject or (ii) rights of any other Person (including
                                         Intellectual Property Rights), and (b) this Agreement is binding upon such Party pursuant
                                         to the laws of such Party’s domicile.

 

    	 	8	 

    	 

    

 

	6.3.	Authorization.
                                         Each of Sirtex and OncoSec has the corporate power and authority to execute and deliver
                                         this Agreement and to perform its obligations hereunder. The execution, delivery and
                                         performance of this Agreement has been duly and validly authorized and approved by all
                                         necessary corporate action on the part of each of Sirtex and OncoSec. Assuming due authorization,
                                         execution and delivery on the part of each Party, this Agreement constitutes a legal,
                                         valid and binding obligation of each such Party, enforceable against such Party in accordance
                                         with its terms.

 

	6.4.	Disclaimer.
                                         EXCEPT FOR THE LIMITED WARRANTIES SET FORTH IN THIS SECTION 6, EACH PARTY EXPRESSLY
                                         DISCLAIMS ALL OTHER REPRESENTATIONS AND WARRANTIES, WHETHER EXPRESS, IMPLIED, STATUTORY,
                                         OR OTHERWISE, IN CONNECTION WITH THIS AGREEMENT OR THE SERVICES, INCLUDING ANY WARRANTIES
                                         OF NON-INFRINGEMENT, OR FITNESS FOR A PARTICULAR PURPOSE.

 

	7.	Indemnification;
                                         Limitation of Liability.
	 	 
	7.1.	Indemnification
                                         by OncoSec. OncoSec agrees to defend, indemnify and hold Sirtex and its Affiliates
                                         and its and their officers, directors, employees, agents, successors and assigns harmless
                                         from and against any and all claims, demands, actions, causes of action, judgments, losses,
                                         damages, costs and expenses (including attorneys’ and expert witness fees and expenses)
                                         (collectively “Losses”) to the extent resulting from any claim, action,
                                         suit, proceeding, liability or obligation asserted by a Third Party (collectively, “Third
                                         Party Claims”) arising out of, relating to or resulting from:

 

		(a)	any
                                         breach of any representation, warranty, covenant or agreement made by OncoSec in this
                                         Agreement;

 

		(b)	the
                                         gross negligence or willful misconduct of OncoSec in connection with this Agreement;
                                         or

 

		(c)	the
                                         development, manufacture, commercialization, or other exploitation of the Products by
                                         OncoSec or its Affiliates or (sub)licensees.

 

	7.2.	Indemnification
                                         by Sirtex. Sirtex agrees to defend, indemnify and hold OncoSec and its Affiliates
                                         and its and their officers, directors, employees, agents, successors and assigns harmless
                                         from and against any and all Losses to the extent resulting from any Third Party Claim
                                         arising out of or relating to or resulting from:

 

		(a)	any
                                         breach of any representation, warranty, covenant or agreement made by Sirtex in this
                                         Agreement; or

 

		(b)	the
                                         gross negligence or willful misconduct of Sirtex in connection with this Agreement.

 

    	 	9	 

    	 

    

 

	7.3.	Indemnification
                                         Procedures.

 

		(a)	Notice
                                         of Claim. All indemnification claims in respect of a Party, its Affiliates or its
                                         or their directors, officers, employees and agents shall be made solely by such Party
                                         to this Agreement (the “Indemnified Party”). The Indemnified Party
                                         shall give the indemnifying Party prompt written notice (an “Indemnification
                                         Claim Notice”) of any Losses or discovery of fact upon which such Indemnified
                                         Party intends to base a request for indemnification under this Section 7; provided that
                                         no failure or delay in providing such notice shall relieve the indemnifying Party of
                                         any liability it may have to the Indemnified Party, except to the extent that such failure
                                         or delay materially prejudices the indemnifying Party with respect to such claim. Each
                                         Indemnification Claim Notice must contain a description of the claim and the nature and
                                         amount of such Loss (to the extent that the nature and amount of such Loss is known at
                                         such time). The Indemnified Party shall furnish promptly to the indemnifying Party copies
                                         of all papers and official documents received in respect of any Losses and Third Party
                                         Claims.

 

		(b)	Control
                                         of Defense. The indemnifying Party shall have the right to assume the defense of
                                         any Third Party Claim by giving written notice to the Indemnified Party within thirty
                                         (30) days after the indemnifying Party’s receipt of an Indemnification Claim Notice.
                                         The assumption of the defense of a Third Party Claim by the indemnifying Party shall
                                         not be construed as an acknowledgment that the indemnifying Party is liable to indemnify
                                         the Indemnified Party in respect of the Third Party Claim, nor shall it constitute a
                                         waiver by the indemnifying Party of any defenses it may assert against the Indemnified
                                         Party’s claim for indemnification. Upon assuming the defense of a Third Party Claim,
                                         the indemnifying Party may appoint as lead counsel in the defense of the Third Party
                                         Claim any legal counsel selected by the indemnifying Party. In the event the indemnifying
                                         Party assumes the defense of a Third Party Claim, the Indemnified Party shall immediately
                                         deliver to the indemnifying Party all original notices and documents (including court
                                         papers) received by the Indemnified Party in connection with the Third Party Claim. Should
                                         the indemnifying Party assume the defense of a Third Party Claim, except as provided
                                         in Section 7.3(c), the indemnifying Party shall not be liable to the Indemnified Party
                                         for any legal expenses subsequently incurred by such Indemnified Party in connection
                                         with the analysis, defense or settlement of the Third Party Claim unless specifically
                                         requested in writing by the indemnifying Party.

 

		(c)	Right
                                         to Participate in Defense. Any Indemnified Party shall be entitled to participate
                                         in the defense of such Third Party Claim and to employ counsel of its choice for such
                                         purpose; provided, however, that such employment shall be at the Indemnified Party’s
                                         sole cost and expense unless (i) the employment thereof has been specifically authorized
                                         by the indemnifying Party in writing (in which case, the defense shall be controlled
                                         as provided in Section 7.3(b)), (ii) the indemnifying Party has failed to assume the
                                         defense and employ counsel in accordance with Section 7.3(b) (in which case the Indemnified
                                         Party shall control the defense), or (iii) the interests of the indemnitee and the indemnifying
                                         Party with respect to such Third Party Claim are sufficiently adverse to prohibit the
                                         representation by the same counsel of both Parties under applicable Law, ethical rules
                                         or equitable principles (in which case, the Indemnified Party shall control its defense).

 

    	 	10	 

    	 

    

 

		(d)	Settlement.
                                         With respect to any Losses relating solely to the payment of money damages in connection
                                         with a Third Party Claim and that shall not result in the applicable indemnitee(s) becoming
                                         subject to injunctive or other relief or otherwise adversely affecting the business of
                                         the Indemnified Party in any manner, the indemnifying Party shall have the sole right
                                         to consent to the entry of any judgment, enter into any settlement or otherwise dispose
                                         of such Loss, on such terms as the indemnifying Party, in its sole discretion, shall
                                         deem appropriate. With respect to all other Losses in connection with Third Party Claims,
                                         where the indemnifying Party has assumed the defense of the Third Party Claim in accordance
                                         with Section 7.3(b), the indemnifying Party shall have authority to consent to the entry
                                         of any judgment, enter into any settlement or otherwise dispose of such Loss; provided
                                         it obtains the prior written consent of the Indemnified Party (which consent shall not
                                         be unreasonably withheld, conditioned or delayed). If the indemnifying Party does not
                                         assume and conduct the defense of a Third Party Claim as provided above, the Indemnified
                                         Party may defend against such Third Party Claim; provided that the Indemnified Party
                                         shall not settle any Third Party Claim without the prior written consent of the indemnifying
                                         Party (which consent shall not be unreasonably withheld, conditioned or delayed).

 

		(e)	Cooperation.
                                         Regardless of whether the indemnifying Party chooses to defend or prosecute any Third
                                         Party Claim, the Indemnified Party shall, and shall cause each indemnitee to, cooperate
                                         in the defense or prosecution thereof and shall furnish such records, information and
                                         testimony, provide such witnesses and attend such conferences, discovery proceedings,
                                         hearings, trials and appeals as may be reasonably requested in connection therewith.
                                         Such cooperation shall include access during normal business hours afforded to the indemnifying
                                         Party to and reasonable retention by the Indemnified Party of, records and information
                                         that are reasonably relevant to such Third Party Claim and making Indemnified Parties
                                         and other employees and agents available on a mutually convenient basis to provide additional
                                         information and explanation of any material provided hereunder and the indemnifying Party
                                         shall reimburse the Indemnified Party for all its, its Affiliates’ and its and
                                         their (sub)licensees’ or their respective directors’, officers’, employees’
                                         and agents’, as applicable, reasonable and verifiable out-of-pocket expenses in
                                         connection therewith.

 

		(f)	Expenses.
                                         Except as provided above, the costs and expenses, including fees and disbursements of
                                         counsel, incurred by the Indemnified Party and its Affiliates and its or their (sub)licensees
                                         and their respective directors, officers, employees and agents, as applicable, in connection
                                         with any claim shall be reimbursed on a Calendar Half basis by the indemnifying Party,
                                         without prejudice to the indemnifying Party’s right to contest the Indemnified
                                         Party’s right to indemnification and subject to refund in the event the indemnifying
                                         Party is ultimately held not to be obligated to indemnify the Indemnified Party.

 

    	 	11	 

    	 

    

 

	7.4.	Insurance
                                         Recovery. Any indemnification hereunder shall be made net of any insurance proceeds
                                         actually recovered by the Indemnified Party from unaffiliated Third Parties; provided,
                                         however, that if, following the payment to the Indemnified Party of any amount under
                                         this Section 7, such Indemnified Party recovers any such insurance proceeds in respect
                                         of the claim for which such indemnification payment was made, the Indemnified Party shall
                                         promptly pay an amount equal to the amount of such proceeds (but not exceeding the amount
                                         of such net indemnification payment) to the indemnifying Party.

 

	7.5.	Exclusive
                                         Remedy. The Parties agree and acknowledge that the provisions of this Section 7 represent
                                         the Indemnified Party’s exclusive recourse with respect to any Losses for which
                                         indemnification is provided to the Indemnified Party under this Section 7.

 

	7.6.	LIMITATION
                                         OF LIABILITY. EXCEPT WITH RESPECT TO EACH PARTY’S INDEMNIFICATION OBLIGATIONS
                                         RESULTING FROM THIRD PARTY CLAIMS OR A BREACH BY EITHER PARTY OF SECTION 9 (CONFIDENTIALITY)
                                         UNDER THIS AGREEMENT, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR
                                         ANY INDIRECT, SPECIAL, CONSEQUENTIAL, INCIDENTAL OR PUNITIVE DAMAGES ARISING FROM THIS
                                         AGREEMENT, INCLUDING LOST PROFITS OR LOSS OF DATA, REGARDLESS OF WHETHER SUCH PARTY HAS
                                         BEEN ADVISED BEFOREHAND OF THE POSSIBILITY OF SUCH DAMAGES. EACH PARTY HEREBY ACKNOWLEDGES
                                         THAT THE FOREGOING LIMITATIONS ARE AN INTEGRAL TERM OF THIS AGREEMENT AND THAT THE OTHER
                                         PARTY WOULD NOT ENTER INTO THIS AGREEMENT WITHOUT SUCH LIMITATIONS.

 

8.
Copyrights and Trademarks.

 

Solely
between OncoSec and Sirtex, all copyrights, trademarks, service marks, trade dress, trade names, logos, corporate names and domain
names, together with all of the goodwill associated therewith (collectively, “Copyrights and Trademarks”) in
and to all marketing collateral, marketing information, and other related finished documents that are delivered by Sirtex to OncoSec
under this Agreement and all logos, product names, or brand names developed by Sirtex in direct connection with the Services and
provided to OncoSec hereunder (collectively, the “Deliverables”) shall be owned exclusively by OncoSec. Sirtex
agrees, and shall cause its employees (collectively, “Sirtex Personnel”) to agree, that with respect to any
Deliverables that may qualify as “work made for hire” as defined in 17 U.S.C. § 101, such Deliverables are hereby
deemed a “work made for hire” for OncoSec. To the extent that any of the Deliverables do not constitute a “work
made for hire,” Sirtex hereby irrevocably assigns, and shall cause the Sirtex Personnel to irrevocably assign to OncoSec,
in each case without additional consideration, all right, title, and interest throughout the world in and to the Deliverables,
including all Copyrights and Trademarks therein. Sirtex shall cause Sirtex Personnel to irrevocably waive, to the extent permitted
by applicable Law, any and all claims such Sirtex Personnel may now or hereafter have in any jurisdiction to so-called “moral
rights” or rights of droit moral with respect to the Deliverables.

 

    	 	12	 

    	 

    

 

	9.	Confidentiality.
	 	 
	9.1.	Definition
                                         of Confidential Information. The Parties acknowledge that, prior to and during the
                                         Term, the Parties may disclose to one another scientific, technical, trade secret, business,
                                         or other information which is treated by the disclosing Party as confidential or proprietary,
                                         including unpublished patent applications and technical information (“Confidential
                                         Information”). Both Parties agree that in order to ensure that each Party understands
                                         which information is deemed to be confidential, all Confidential Information will be
                                         in written form and clearly marked as “Confidential,” and if the Confidential
                                         Information is initially disclosed in oral or some other non-written form, it will be
                                         confirmed and summarized in writing and clearly marked as “Confidential”
                                         within thirty (30) days of disclosure. The receiving Party shall hold such Confidential
                                         Information in confidence and shall treat such information in the same manner as it treats
                                         its own confidential information but with not less than with a reasonable degree of care.
                                         The Confidential Information provided to the receiving Party will remain the property
                                         of the disclosing Party, and will be disclosed or used only as necessary or reasonably
                                         useful for the performance of this Agreement or the exercise of rights or licenses granted
                                         hereunder.

 

	9.2.	Exclusions.
                                         Confidential Information does not include information that (a) was known to the receiving
                                         Party prior to receipt from the disclosing Party as evidenced by the receiving Party’s
                                         records; (b) is or becomes part of the public domain through no breach of this Agreement
                                         by the receiving Party; (c) is lawfully received by the receiving Party from a Third
                                         Party that is not bound by any obligations of confidentiality with respect to such information;
                                         or (d) comprises identical subject matter to that which had been originally and independently
                                         developed by or for the receiving Party without knowledge or use of any Confidential
                                         Information as evidenced by written records.

 

	9.3.	Permitted
                                         Disclosures. Notwithstanding the foregoing, the receiving Party may disclose the
                                         Confidential Information of the disclosing Party (a) as and to the extent required by
                                         the order of any Governmental Authority of competent jurisdiction; provided that the
                                         receiving Party shall, to the extent permitted by applicable Law, use reasonable efforts
                                         to notify the disclosing Party of such proposed disclosure in such a manner and on such
                                         a schedule as will afford the disclosing Party a reasonable opportunity to seek a protective
                                         order or similar restriction on disclosure of the disclosing Party’s Confidential
                                         Information proposed to be disclosed by the receiving Party, (b) as required by applicable
                                         Law or the rules of a stock exchange on which its securities are listed (or to which
                                         an application for listing has been submitted) to make a disclosure that describes or
                                         refers to the terms and conditions of this Agreement or any related agreements between
                                         the Parties, (c) to the extent that such disclosure is made to regulatory authorities
                                         as deemed reasonably necessary by the receiving Party in connection with any filing,
                                         application, or request for regulatory approval, response to any requests or inquiries
                                         from a regulatory authority, or other communication with a regulatory authority, and
                                         (d) to prospective acquirers, lenders, investors, collaboration partners, and (sub)licensees
                                         that agree to be bound by non-use and non-disclosure obligations in respect of such Confidential
                                         Information.

 

	9.4.	Press
                                         Releases and Other Announcements. Notwithstanding anything to the contrary in this
                                         Agreement, neither Party shall issue a press release or otherwise make a public announcement
                                         concerning the subject matter of this Agreement without the prior review and written
                                         approval of the text of any such press release or other public announcement by the other
                                         Party. The non-disclosing Party shall not unreasonably withhold or delay such review
                                         and approval.

 

    	 	13	 

    	 

    

 

	9.5.	Duration.
                                         Except as otherwise provided herein, the restrictions and covenants set forth in this
                                         Section 9 shall survive until the [ * ] year anniversary of the date that this
                                         Agreement is terminated or expires; provided, however, that with respect to Confidential
                                         Information that constitutes a trade secret under applicable Law, the receiving Party’s
                                         obligations pursuant to this Section 9 shall survive so long as such Confidential Information
                                         remains a trade secret under applicable Law.

 

	10.	General
                                         Provisions.
	 	 
	10.1.	Notices.
                                         Section 11.3 (Notices) of the Stock Purchase Agreement is hereby incorporated by reference
                                         as though set forth herein, mutatis mutandis.

 

	10.2.	Assignment.
                                         Neither Party shall assign any of its rights or delegate any of its obligations hereunder
                                         without the prior written consent of the other Party; provided, however, that either
                                         Party may assign its rights or delegate its obligations, in whole or in part, without
                                         such consent (but with written notice to the other Party, to be provided not more than
                                         thirty (30) days’ following such assignment or delegation), to (a) one or more
                                         of its Affiliates; or (b) an entity that acquires all or substantially all of the business
                                         or assets of such Party to which this Agreement pertains; in each case whether by merger,
                                         reorganization, acquisition, sale, or otherwise. The assigning Party will remain responsible
                                         for the performance by its assignee of any obligation hereunder so assigned. Any purported
                                         assignment or transfer in violation of this Section 10.2 will be void and of no force
                                         and effect.

 

	10.3.	Waiver.
                                         Section 11.10 (Waiver) of the Stock Purchase Agreement is hereby incorporated by reference
                                         as though set forth herein, mutatis mutandis.

 

	10.4.	Governing
                                         Law, Jurisdiction, and Venue.

 

		(a)	Governing
                                         Law. The construction, interpretation and performance of this Agreement shall be
                                         governed by and construed in accordance with the internal laws of the State of New York,
                                         without regard to its rules or procedures involving conflicts of laws.

 

		(b)	Jurisdiction.
                                         The Parties hereby irrevocably and unconditionally consent to the exclusive jurisdiction
                                         of the courts of the State of New York or the United States District Court for the Southern
                                         District of New York for any action, suit or proceeding (other than appeals therefrom)
                                         arising out of or relating to this Agreement and agree not to commence any action, suit
                                         or proceeding (other than appeals therefrom) related thereto except in such court. The
                                         Parties irrevocably and unconditionally waive their right to a jury trial.

 

		(c)	Venue.
                                         The Parties further hereby irrevocably and unconditionally waive any objection to the
                                         laying of venue of any action, suit or proceeding (other than appeals therefrom) arising
                                         out of or relating to this Agreement in the courts of the State of New York or the United
                                         States District Court for the Southern District of New York and hereby further irrevocably
                                         and unconditionally waive and agree not to plead or claim in such court that any such
                                         action, suit or proceeding brought in such court has been brought in an inconvenient
                                         forum.

 

    	 	14	 

    	 

    

 

	10.5.	Dispute
                                         Resolution.

 

		(a)	Litigation.
                                         Any claim, dispute, or controversy of whatever nature arising between the Parties out
                                         of or relating to this Agreement that is not resolved under Section 4.4 within the applicable
                                         forty-five (45) day time period, including any action or claim based on tort, contract,
                                         or statute (including any claims of breach or violation of statutory or common law protections
                                         from discrimination, harassment and hostile working environment), or concerning the interpretation,
                                         effect, termination, validity, performance or breach of this Agreement, may, upon notice
                                         by either Party to the other Party, be resolved by litigation in accordance with Section
                                         10.4.

 

		(b)	No
                                         Limitation on Equitable Relief. Neither Section 4.4 nor Section 10.5(a) shall limit
                                         or constrain either Party’s ability to seek equitable relief and either Party may
                                         institute proceedings therefor in accordance with Section 10.4 without resort to the
                                         procedures described in Sections 4.4 and 10.5(a).

 

	10.6.	Entire
                                         Agreement. Section 11.8(a) of the Stock Purchase Agreement is hereby incorporated
                                         by reference as though set forth herein, mutatis mutandis.

 

	10.7.	Amendments.
                                         This Agreement may not be modified or amended except in a writing signed by a duly authorized
                                         officer or representative of each Party.

 

	10.8.	Severability.
                                         If any provision of this Agreement is held to be illegal, invalid or unenforceable under
                                         any present or future law and if the rights or obligations of either Party under this
                                         Agreement will not be materially and adversely affected thereby, (a) such provision shall
                                         be fully severable, (b) this Agreement shall be construed and enforced as if such illegal,
                                         invalid or unenforceable provision had never comprised a part hereof, (c) the remaining
                                         provisions of this Agreement shall remain in full force and effect and shall not be affected
                                         by the illegal, invalid or unenforceable provision or by its severance herefrom, and
                                         (d) in lieu of such illegal, invalid or unenforceable provision, there shall be added
                                         automatically as a part of this Agreement a legal, valid and enforceable provision as
                                         similar in terms to such illegal, invalid or unenforceable provision as may be possible
                                         and reasonably acceptable to the Parties. To the fullest extent permitted by applicable
                                         Law, each Party hereby waives any provision of law that would render any provision hereof
                                         illegal, invalid or unenforceable in any respect.

 

	10.9.	Relationship
                                         Of The Parties. It is expressly agreed that OncoSec, on the one hand, and Sirtex,
                                         on the other hand, shall be independent contractors and that the relationship between
                                         the Parties shall not constitute a partnership, joint venture or agency. Neither OncoSec,
                                         on the one hand, nor Sirtex, on the other hand, shall have the authority to make any
                                         statements, representations or commitments of any kind or to take any action that will
                                         be binding on the other Party without the prior written consent of the other Party to
                                         do so. All individuals employed by a Party shall be employees of such Party and not of
                                         the other Party and all costs and obligations incurred by reason of any such employment
                                         shall be for the account and expense of such first Party.

 

	10.10.	No
                                         Benefit To Others. Section 11.5 (No Benefit to Others) of the Stock Purchase Agreement
                                         is hereby incorporated by reference as though set forth herein, mutatis mutandis.

 

	10.11.	Headings
                                         And Gender; Construction; Interpretation. Section 11.6 (Headings and Gender; Construction;
                                         Interpretation) of the Stock Purchase Agreement is hereby incorporated by reference as
                                         though set forth herein, mutatis mutandis.

 

	10.12.	Counterparts.
                                         Section 11.7 (Counterparts) of the Stock Purchase Agreement is hereby incorporated by
                                         reference as though set forth herein, mutatis mutandis.

 

	10.13.	Effect
                                         of Termination or Expiration of Stock Purchase Agreement. For the avoidance of doubt,
                                         the provisions incorporated herein by reference from the Stock Purchase Agreement shall,
                                         to the extent incorporated herein, survive any termination or expiration of the Stock
                                         Purchase Agreement.

 

[SIGNATURE
PAGE FOLLOWS]

 

    	 	15	 

    	 

    

 

IN
WITNESS WHEREOF, the Parties have caused this Agreement to be executed as of the date first above written.

 

	OncoSec:
                                         

OncoSec
Medical Incorporated

	 	Sirtex:
                                         

Sirtex
Medical US Holdings, Inc.

	 	 	 	 	 
	By:	/s/
    Daniel J. O’Connor	 	By:
    	/s/
    Kevin R. Smith
	Name:
    	Daniel
    J. O’Connor	 	Name:
    	Kevin
    R. Smith
	Title:	Chief
    Executive Officer and President	 	Title
    :	Chief
    Executive Officer

 

[Signature
Page – Services Agreement between OncoSec and Sirtex]

 

    	 	 	 

    	 

    

 

Exhibit
A

 

Services

 

Sirtex
will provide Services within the following categories to OncoSec during the Term. The JSC shall detail in individual work plans
the specific aspects and timelines for the provision of these Services.

 

The
general categories of Services shall include:

 

	 	●	Key
    Opinion Leader Management and Engagement

	 	o	[
                                         * ]

	 	o	[
                                         * ]

	 	●	Voice
    of Customer (VOC)

	 	o	[
                                         * ]

	 	o	[
                                         * ]

	 	o	[
                                         * ]

	 	●	Development
    of Go to Market Strategy

	 	o	[
                                         * ]

	 	o	[
                                         * ]

	 	o	[
                                         * ]

	 	●	Pricing,
    Reimbursement & Market Access 

	 	o	[
                                         * ]

	 	o	[
                                         * ]Execution
Version

 

STOCKHOLDERS
AGREEMENT

 

THIS
STOCKHOLDERS AGREEMENT (as may be amended or modified from time to time, this “Agreement”) is made and
entered into as of October 10, 2019, by and between OncoSec Medical Incorporated, a Nevada corporation (the “Company”),
and Grand Decade Developments Limited, a British Virgin Islands limited company and a wholly owned subsidiary of China Grand Pharmaceutical
and Healthcare Holdings Limited (“Buyer”).

 

RECITALS

 

WHEREAS,
Buyer and the Company have entered into that certain Stock Purchase Agreement, dated as of the date of this Agreement (the “SPA”);
and

 

WHEREAS,
the parties hereto have agreed that Buyer would receive certain rights, including with respect to the appointment of directors
to the board of directors of the Company (the “Board of Directors”), as set forth herein.

 

NOW,
THEREFORE, in consideration of the foregoing and the respective representations and warranties, covenants and agreements set
forth in this Agreement and the SPA, and other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, effective as of the Closing (as defined in the SPA) the parties hereto agree as follows:

 

1. Definitions.
Capitalized terms used but not defined in this Agreement shall have the respective meanings ascribed to them in the SPA.

 

For
purposes of this Agreement:

 

“Beneficial
Ownership” has the meaning assigned to such term in Rule 13d-3 under the 1934 Act, and a Person’s beneficial ownership
of securities shall be calculated in accordance with the provisions of such Rule (it being agreed that, in any event, a Person
shall be deemed to Beneficially Own securities owned by an Affiliate of such Person).

 

For
the avoidance of doubt, “Purchased Shares” shall have the meaning set forth in the SPA, and shall take into
account any Recapitalization event that may occur at any time.

 

    	 	 	 

    	 

    

 

2. Board
of Directors.

 

(a) At
the Closing, and thereafter, at any time that Buyer Beneficially Owns at least 40% of the Purchased Shares, Buyer shall have the
right to nominate (i) two (2) (of the nine total) members to the Board of Directors pursuant to this Section 2 (the “Buyer
Directors”), initially at the Closing, and thereafter at every annual meeting of the stockholders of the Company in
which directors are generally elected, including at every adjournment or postponement thereof, and on any action by written consent
of the stockholders of the Company relating to the election of directors generally and (ii) up to two (2) independent directors
at the time any independent director currently serving on the Board of Directors ceases to serve as a director of the Company
for any reason; provided, however, that the suitability of any such independent director nominee shall be reasonably
satisfactory to a majority of the independent directors of the Company, and the Company shall maintain compliance with Rule 5605
of The Nasdaq Stock Market (“Nasdaq”) and the rules and regulations of the SEC (at all times). The Buyer Directors
shall be appointed to authorized committees of the Board of Directors in proportion with the Buyer Directors’ representation
on the Board of Directors. If Buyer Beneficially Owns less than 40% of the Purchased Shares, Buyer shall have the right to nominate
members to the Board of Directors in proportion with Buyer’s ownership of the issued and outstanding Common Stock. Immediately
prior to the Closing, the Company shall cause the chair of the Board of Directors to be an independent director. The limitations
on Buyer’s ability to nominate and elect any number of directors to the Board of Directors shall terminate if a “group”
(as defined under the 1934 Act) or Person unaffiliated with Buyer Beneficially Owns 20% or more of the outstanding Common Stock.

 

(b) The
following procedures shall be followed with respect to the nomination of Buyer Directors pursuant to this Section 2:

 

(i) For
purposes of whether Buyer has a right to nominate a Buyer Director pursuant to this Section 2, the Beneficial Ownership
of the Common Stock of Buyer will be initially measured as of the Closing and thereafter as of the record date for such annual
meeting or written consent.

 

(ii) At
least 20 days prior to the Closing, Buyer shall provide the Company with the identity of the initial Buyer Directors to be appointed
to the Board of Directors as of the Closing (provided that Buyer may substitute such appointees by notice to the Company at least
20 days prior to the Closing). Following the initial appointment of Buyer Directors, each year, the Company will notify Buyer
when it intends to hold its next Company’s annual meeting of stockholders at least 90 days prior to such meeting. With respect
to Buyer’s nominees (other than the initial Buyer Directors), at least 60 days prior to the Company’s annual meeting
of stockholders, Buyer shall provide the Company with the Buyer’s nominees for the Buyer Directors.

 

(iii) The
Board of Directors shall (1) in the case of the initial Buyer Directors, appoint the Buyer Directors as members of the Board of
Directors effective as of the Closing to serve until the Company’s next annual meeting of stockholders at which directors
will be generally elected, and (2) in the case of subsequent Buyer Directors, nominate such nominees to be elected as directors
and recommend that the stockholders vote to elect such nominees at the next annual meeting of stockholders at which directors
will be generally elected.

 

    	 	2	 

    	 

    

 

(iv) If
Buyer nominee(s) is not appointed, nominated or elected by the stockholders, then as soon as practicable after the Closing or
annual meeting, as applicable, Buyer shall designate nominee(s) for such Buyer Director(s), which nominee(s) shall be appointed
as director(s) by the Board of Directors promptly after such designation.

 

(c) Each
of the Buyer Directors will be governed by the same protections and obligations as all other directors of the Company, including,
without limitation, protections and obligations regarding customary liability insurance for directors and officers, confidentiality,
conflicts of interests, fiduciary duties (subject to Section 6), trading and disclosure policies, director evaluation process,
director code of ethics, director share ownership guidelines, stock trading and pre-approval policies, and other governance matters.
Each Buyer Director agrees that he or she shall be bound by the Company’s insider trading policy. The Company shall use
commercially reasonable efforts to ensure that the Buyer Directors are covered by liability insurance for directors with coverage
that is at least as favorable, in the aggregate, to such directors as the coverage provided for by insurance policies acquired
by the Company for the benefit of directors of the Company as in effect as of the date of this Agreement.

 

(d) A
quorum for meetings of the Board of Directors (and written consents executed by directors) must include at least one (1) Buyer
Director.

 

(e) The
Buyer Directors shall not be compensated for their service on the Board of Directors, but shall be reimbursed for expenses incurred
in connection with their service as members of the Board of Directors.

 

3. Voting
Requirements.

 

(a) Until
such time that Buyer Beneficially Owns less than 40% of the Purchased Shares, none of the actions set forth in this Section
3 below shall be taken by, or on behalf of, directly or indirectly, the Company (or any Subsidiary thereof) without the approval
of at least 70% of the members constituting the entire Board of Directors, and until such time that Buyer Beneficially Owns less
than 70% of the Purchased Shares, none of the actions set forth in this Section 3 below shall be taken by, or on behalf
of, directly or indirectly, the Company (or any Subsidiary thereof) without the consent of Buyer:

 

(i) Amending
the Articles of Incorporation or the Bylaws;

 

(ii) Increasing
the size of the Board of Directors to more than nine;

 

(iii) Declaring,
setting aside or paying any dividend or other distribution (whether in cash, stock or property or any combination thereof);

 

(iv) Redeeming,
repurchasing or otherwise acquiring any Issuer Securities;

 

    	 	3	 

    	 

    

 

(v) Issuing,
pledging, disposing of, transferring, encumbering, granting, selling or otherwise delivering, or authorizing the issuance, pledge,
disposal of, transfer, encumbrance, grant, sale or other delivery of, any Issuer Securities; provided, however,
that issuances of an Issuer Security pursuant to an Issuer Stock Option or Issuer Warrant existing as of the date hereof or under
the ESPP shall not require the approval of 70% of the Board of Directors or the consent of Buyer unless such issuance would result
in Buyer and Sirtex Medical US Holdings, Inc., in the aggregate, holding, directly or indirectly, less than 50.1% of any class
or series of Issuer Securities on a fully diluted basis (taking into account all options, warrants, convertible securities and
obligations to issue the same);

 

(vi) Creating
or incurring any indebtedness or Lien on any of the Company’s or its Subsidiaries’ assets, in excess of $250,000;

 

(vii) Selling,
assigning, leasing, licensing or otherwise transferring, abandoning, disposing of or permitting to lapse any of the Company’s
or its Subsidiaries’ assets;

 

(viii) Incurring
any capital expenditures or any obligations or liabilities in respect thereof in excess of $500,000;

 

(ix) Approving
the Company’s annual budget;

 

(x) Making
any loans, advances or capital contributions to, or investments in, any other Person; and

 

(xi) Entering
into any agreement with a Related Party.

 

4. Right
of Participation.

 

(a) Following
the date of this Agreement until any time that Buyer Beneficially Owns less than 60% of the Purchased Shares, Buyer shall have
the right to purchase, on a pro rata basis, any New Securities that the Company may from time to time sell or issue. For purposes
hereof, “pro rata basis” shall mean a percentage of the New Securities equal to Buyer’s Beneficial Ownership
of the Company’s outstanding common stock expressed as a percentage as calculated immediately after the Closing.

 

    	 	4	 

    	 

    

 

(b) The
Company shall provide Buyer with written notice its intention to issue New Securities, which notice shall be provided, subject
to the Company’s reasonable best efforts, not less than 30 days prior to the date of such proposed issuance (the Company
will use reasonable efforts to provide longer notice, if possible) (such period between such notice and the date of such issuance
or the expected date of entry into such contract, if applicable, a “Notice Period”), and the Company shall
provide Buyer with written notice of the actual issuance of such New Securities not less than 24 hours prior to such issuance
(also, a “Notice Period”), including in each case, if applicable, a copy of the prospectus included in the
registration statement filed in respect of such offering or, in the case of an offering exempt from registration, the private
placement memorandum or similar offering documents or term sheet in respect of such offering, (i) describing (A) the anticipated
amount of New Securities, price (if reasonably known) and other available (or reasonably determinable) material terms upon which
the Company offers to sell New Securities, and (B) the number of New Securities Buyer is entitled to purchase pursuant to this
Section 4, and (ii) containing a binding offer to sell New Securities to Buyer subject to the consummation of such issuance.
If prior to any such issuance, there is a material change in the terms of such issuance, then prior to such issuance, the Company
shall provide Buyer with ten (10) Business Days’ prior written notice describing such change (such period between such notice
and the date of such issuance, also a “Notice Period”).

 

(c) Buyer
may exercise its right to purchase any New Securities by providing written notice to the Company prior to the expiration of the
applicable Notice Period. Buyer’s notice must indicate the specific amount of New Securities that Buyer desires to purchase
and shall constitute exercise by Buyer of its rights under this Section 4 and a binding agreement of Buyer to purchase
the number (or amount) of New Securities specified in Buyer’s written notice. If, at the expiration of a Notice Period,
Buyer shall not have delivered written notice to the Company exercising its right to effect a purchase, Buyer shall be deemed
to have waived all of its rights under this Section 4 solely with respect to such specific issuance. Buyer shall effect
such purchase concurrently with such issuance (the date of consummation of such transactions, the “Preemptive Rights
Closing Date”).

 

(d) Except
as provided in Section 4(e), if the Company issues New Securities and Buyer exercises its right to purchase any such New
Securities, Buyer shall pay an amount in cash per security equal to the cash consideration per security paid by the other purchasers
of such New Securities in such issuance; provided that in the case of a private placement offering under Rule 144A of the
1933 Act or similar transaction, the price paid by Buyer shall not include (and shall be reduced by the amount of) any underwriting
or initial purchaser’s discount or fees (as disclosed in the final prospectus, offering memorandum or other similar documentation)
incurred by Issuer in a related public offering.

 

(e) If
the Company issues New Securities for non-cash consideration (or a combination of cash and non-cash consideration), and Buyer
exercises its right to purchase any such New Securities, Buyer shall pay in cash, per security in such purchase, the volume-weighted
average price per share of the Common Stock over the preceding 20 trading days (from the earlier of (i) the date of the Preemptive
Rights Closing Date and (ii) the date such issuance is publicly announced) on Nasdaq.

 

(f) In
the event that a proposed issuance of New Securities is terminated or abandoned by the Company without the issuance of any New
Securities, then Buyer’s purchase rights pursuant to this Section 4 shall also terminate as to such proposed issuance,
and any funds in respect thereof paid to the Company by Buyer shall be refunded promptly and in full.

 

    	 	5	 

    	 

    

 

(g) “New
Securities” shall mean any debt or equity securities of the Company or any subsidiary of the Company, whether or not
now authorized, and rights, options or warrants to purchase such debt or equity securities, and securities of any type whatsoever
that are, or may become, convertible into or exchangeable for such debt or equity securities; provided, that the term “New
Securities” does not include:

 

(i) shares
of the Company’s Common Stock (and/or options, rights or warrants for Common Stock) issued or issuable in connection with
an acquisition transaction or other merger and acquisition transaction, strategic alliance or partnering/licensing arrangement
that is approved by 80% of the members constituting the entire Board of Directors;

 

(ii) any
securities issuable upon exercise of any options, warrants or rights to purchase any securities of the Company outstanding on
the date of this Agreement;

 

(iii) any
securities issued pursuant to equity plans of the Company (including inducement awards or any arrangements in place as of the
date of this Agreement); and

 

(iv) shares
of the Company’s Common Stock issued in connection with any stock split or stock dividend.

 

5. Right
of First Refusal.

 

(a) Following
the date of this Agreement until any time that Buyer Beneficially Owns less than 60% of the Purchased Shares, the Company shall
deliver written notice (the “ROFR Notice”) to Buyer prior to entering into any definitive agreement regarding
any material licensing transaction or Competing Proposal (a “ROFR Transaction”). The ROFR Notice shall contain
(i) a description of the structure of the ROFR Transaction, including the assets or securities to be sold or acquired by the Third
Party pursuant to the ROFR Transaction (the “Company Interests”), (ii) the purchase price therefor, including
a description of any non-cash consideration sufficiently detailed to permit valuation thereof, (iii) the identity of the proposed
Third Party and (iv) any other material terms and conditions of the proposed ROFR Transaction, including the proposed closing
date. By delivering the ROFR Notice, the Company represents and warrants to Buyer that: (1) the Company has full right, title
and interest in and to the Company Interests; (2) the Company has all the necessary power and authority and has taken all necessary
action to sell the Company Interests as contemplated by this Section 5; and (3) the Company Interests are free and clear
of any and all Liens other than those arising as a result of or under the terms of this Agreement.

 

    	 	6	 

    	 

    

 

(b) The
ROFR Notice shall be accompanied by a written offer (the “ROFR Offer”), irrevocable until the end of the ROFR
Exercise Period (as defined below), to sell the Company Interests on the same terms and conditions as set forth in the ROFR Notice
to Buyer (or one or more Affiliates designated by Buyer) (except if non-cash consideration is to be paid, then the purchase price
shall be an amount in cash equal to 100.00% of the cash purchase price and 100% of the fair market value of any non-cash consideration
set forth in the ROFR Notice).

 

(c) Buyer
shall have 60 days from the date on which it receives the applicable ROFR Notice (the “ROFR Exercise Period”)
to determine whether to accept the ROFR Offer to purchase all (but not less than all) of the Company Interests; provided
that the ROFR Exercise Period shall not be deemed to have commenced until a determination of fair market value of any non-cash
consideration set forth in the ROFR Notice has been made in accordance with Section 5(b) above; provided, further,
that in no event shall the ROFR Exercise Period exceed 90 days. If Buyer desires to accept the ROFR Offer, it shall give written
notice (a “Notice of Election”) to the Company of its intent to accept such ROFR Offer during the ROFR Exercise
Period. The Company shall cooperate with Buyer’s reasonable diligence requests during the ROFR Exercise Period and shall
provide customary representations, warranties, covenants and indemnities in connection with any such transaction. The failure
of Buyer to give a Notice of Election to the Company by the end of the ROFR Exercise Period shall constitute a waiver of Buyer’s
right of first refusal under this Section 5 with respect to the Company Interests subject to the applicable ROFR Notice,
but shall not affect its rights with respect to any future ROFR Notice. A Notice of Election shall constitute a binding agreement
between the Company and Buyer. The closing of the transaction shall take place at the principal offices of the Company (or such
other location as Buyer and the Company may agree) three (3) Business Days following the satisfaction or waiver of the conditions
to closing for such ROFR Transaction.

 

(d) In
the event that Buyer shall not elect to purchase all of the Company Interests, then, provided the Company has complied with the
provisions of this Section 5, the Company may sell all (but not less than all) of the Company Interests to the prospective
Third Party identified in the ROFR Notice on the same terms and conditions set forth therein, during the 60 calendar day period
immediately following the expiration of the ROFR Exercise Period; provided that such date of closing shall be extended
to the extent necessary to obtain any required regulatory approvals (but in no event shall such date be greater than 180 calendar
days after the expiration of the ROFR Exercise Period). Any Company Interests not sold within such period will be subject to the
provisions of this Section 5 upon any subsequent sale. If the Company Interests represent all of the Company’s assets,
the intangible rights appurtenant to the Company Interests shall also transfer to the Third Party involved in such sale.

 

    	 	7	 

    	 

    

 

6. Corporate
Opportunity Waiver.

 

To
the maximum extent permitted from time to time by Applicable Law, (i) the Company renounces any interest or expectancy of the
Company in, or in being offered an opportunity to participate in, business opportunities that are from time to time presented
to Buyer, the Buyer Directors, any other Person or Persons who are, at the time, associated with or nominated by, or serving as
Representatives of Buyer, or the respective Affiliates of the foregoing parties (including their officers or directors who are
employees, officers, directors, managers, stockholders or members) (the “Covered Persons”), (ii) none of such
Covered Persons shall have any obligation to refrain from (a) engaging in similar activities or lines of business as the Company
or developing or marketing any products or services that compete, directly or indirectly, with those of the Company, (b) investing
or owning any interest publicly or privately in, serving as a director or officer of or developing a business relationship with,
any Person engaged in similar activities or lines of business as, or otherwise in competition with, the Company, (c) doing business
with any client or customer of the Company or (d) employing or otherwise engaging a former officer or employee of the Company,
and (iii) neither the Company nor any of its Subsidiaries shall have any right to be offered any opportunity to participate or
invest in any venture engaged or to be engaged in by any Covered Person.

 

7. Representations
and Warranties.

 

Each
of the parties hereto represents and warrants as follows:

 

(a) Each
party hereto: (i) is a legal entity duly incorporated or organized, as applicable, validly existing and in good standing under
the laws of its place of incorporation or organization, (ii) is duly licensed and qualified to conduct its business in each jurisdiction
where the nature of the properties owned, leased or operated by it and the business transacted by it requires such licensing or
qualification, except where any such failures to be so qualified or licensed have not had, or are not reasonably likely to have,
a material adverse effect on the ability of such party to perform its obligations under or to consummate the transactions contemplated
by this Agreement, and (iii) holds all necessary corporate power and authority to own, license and operate its assets and properties,
to conduct its business, to enter into this Agreement, to perform its obligations hereunder and to consummate the transactions
contemplated hereby.

 

(b) The
execution and delivery of this Agreement by each party hereto and the performance by such party of its obligations hereunder have
been duly authorized by all requisite action on the part of such party, and no other actions or proceedings on the part of such
party are necessary to authorize the execution and delivery of this Agreement.

 

(c) This
Agreement has been duly executed and delivered by each party hereto and constitutes the valid and binding agreement of such party,
enforceable against such party in accordance with its terms.

 

(d) The
execution or delivery by each party hereto of this Agreement or the performance by such party of its obligations under this Agreement
will not (i) result in any breach of any provision of such party’s certificate of incorporation or bylaws (if applicable),
(ii) result in any breach of, require (with or without notice or lapse of time or both) any payment, consent or notice or constitute
a default (or give rise to any right of purchase, termination, amendment, acceleration or cancellation) under any Contract or
order or judgment to which such party is a party or by which it or its assets are bound, (iii) result in the creation of an encumbrance,
or (iv) violate any applicable legal requirement, other than, in the case of clauses (ii) through (iv), such breaches,
defaults or violations that have not had, or are not reasonably likely to have, a material adverse effect on the ability of such
party to perform its obligations under or to consummate the transactions contemplated by this Agreement.

 

    	 	8	 

    	 

    

 

8. 
Access and Information.

 

From
the date hereof and subject to Applicable Law, the Company shall (i) give to Buyer and its Representatives reasonable access to
the offices, properties, assets, books and records of the Company and its Subsidiaries, (ii) furnish to Buyer and its Representatives
such financial and operating data, including without limitation, annual budget plan and annual cash flow projection, and other
information as such Persons may reasonably request and (iii) instruct the Representatives of the Company and its Subsidiaries
to cooperate with Buyer in its investigation of the Company and its Subsidiaries. Any investigation pursuant to this Section
8 shall be conducted in such manner as not to interfere unreasonably with the conduct of the business of the Company and its
Subsidiaries.

 

9. 
Termination. 

 

Notwithstanding
anything in this Agreement to the contrary, this Agreement shall terminate in its entirety when Buyer Beneficially Owns less than
20% of the Purchased Shares. Notwithstanding the preceding sentence, nothing in this Section 9 shall relieve or otherwise
limit any party of liability for willful breach of this Agreement.

 

10. Miscellaneous.

 

(a) Entire
Agreement. This Agreement, together with all other documents referred to herein, constitutes the entire agreement between
the parties hereto with respect to the subject matter of this Agreement and supersedes any and all prior agreements, negotiations,
correspondence, undertakings, understandings and communications of the parties hereto with respect to the subject matter of this
Agreement. Nothing contained in this Agreement shall be deemed or construed as creating a joint venture or partnership between
any of the parties hereto.

 

(b) Transaction
Costs. Except as otherwise provided herein or in the SPA, the parties to this Agreement will pay their own costs and expenses
(including legal, accounting and other fees) relating to this Agreement.

 

(c) Modifications.
Any amendment or modification to this Agreement, including this undertaking itself, shall only be valid if effected by an instrument
or instruments in writing and shall be effective against each of the parties hereto that has signed such instrument or instruments.
The parties hereto agree that they jointly negotiated and prepared this Agreement and that this Agreement will not be construed
against any party on the grounds that such party prepared or drafted the same.

 

    	 	9	 

    	 

    

 

(d) Notices.
Notices will be deemed to have been received (a) upon receipt of a registered letter, (b) three Business Days following proper
deposit with an internationally recognized express overnight delivery service, or (c) in the case of transmission by email, as
of the date so transmitted (or if so transmitted after normal business hours at the place of the recipient, on the Business Day
following such transmission):

 

If
to the Company:

 

	 	OncoSec Medical
    Incorporated
	 	24 North
    Main Street
	 	Pennington, NJ 08534-2218
	 	 
	 	Attention: Daniel
    J. O’Connor
	 	E-mail: docconor@oncosec.com

 

With
a copy (which shall not constitute notice) to:

 

	 	Alston
    & Bird LLP
	 	90 Park
    Avenue, 12th Floor
	 	New
    York, NY 10016
	 	Attention:	James H. Sullivan, Esq.
	 	 	Matthew W. Mamak, Esq.
	 	E-mail:	james.sullivan@alston.com
	 	 	matthew.mamak@alston.com

 

if
to Buyer to:

 

	 	Grand
    Decade Developments Limited
	 	Unit
    3302, The Center, 99 Queen’s Road Central
	 	Hong
    Kong
	 	Attention:	Zhou Chao
	 	E-mail:	zhouchao@chinagrandinc.com

 

with
a copy (which shall not constitute notice) to:

 

	 	Covington
    & Burling LLP
	 	The
    New York Times Building
	 	620
    Eighth Avenue
	 	New
    York, New York 10018
	 	Attention: 	Jack S. Bodner
	 		Stephen A. Infante
	 	Facsimile No.:	646-441-9079
	 	 	646-441-9039
	 	E-mail:	jbodner@cov.com
	 	 	sinfante@cov.com

 

or
to such other address as may be hereafter communicated in writing by the parties hereto in a notice given in accordance with this
Section 10(d), which address shall then apply to the respective notice provisions of the SPA and all other Ancillary Agreements.

 

    	 	10	 

    	 

    

 

(e) Severability.
Each provision of this Agreement will be interpreted in such manner as to be effective and valid under Applicable Law, but if
any provision of this Agreement is found to be unenforceable or invalid under Applicable Law, such provision will be ineffective
only to the extent of such unenforceability or invalidity, and the parties hereto will negotiate in good faith to modify this
Agreement so that the unenforceable or invalid provision is replaced by such valid and enforceable provision which the parties
hereto consider, in good faith, to match as closely as possible the invalid or unenforceable provision and to achieve the same
or a similar economic effect and to give effect to the parties’ original intent. The remaining provisions of this Agreement
will continue to be binding and in full force and effect.

 

(f) Assignment.
No party hereto may assign, in whole or in part, or delegate all or any part of its rights, interests or obligations under this
Agreement without the prior written consent of the other party. Any assignment or delegation made without such consent will be
void. Notwithstanding the foregoing, Buyer shall be entitled to (a) assign its rights under this Agreement to any one of its Affiliates,
and (b) assign any or all of its rights and obligations under this Agreement (in whole or in part) as collateral security in a
financing transaction.

 

(g) Confidentiality
Agreement. The terms of the Confidentiality Agreement are hereby incorporated herein by reference and will continue in full
force and effect until expiration or termination in accordance with the terms therein.

 

(h) Governing
Law. Except to the extent that mandatory principles of Applicable Law require the application of the NRS, this Agreement shall
be governed by and construed in accordance with the laws of the State of New York, without giving effect to any choice or conflict
of law provision or rule (whether of the State of New York or any other jurisdiction) that would cause the application of laws
of any jurisdiction other than those of the State of New York.

 

(i) Specific
Performance. Each party hereto acknowledges and agrees that the other party would be irreparably damaged if the provisions
of this Agreement are not performed in accordance with their terms and that any breach of this Agreement and the non-consummation
of the transactions contemplated hereby by either party could not be adequately compensated in all cases by monetary damages alone.
Accordingly, in addition to any remedy to which such other party may be entitled under Section 10(j), provisional measures
and injunctive relief necessary to protect the possibility of each party to seek specific performance from the other from the
tribunal referred to in Section 10(j) can be sought from any court of competent jurisdiction. Each of the parties hereto
(i) agrees that it shall not oppose the granting of any such relief and (ii) hereby irrevocably waives any requirement for the
security or posting of any bond in connection with any such relief (it is understood that clause (i) of this sentence is
not intended to, and shall not, preclude any party hereto from litigating on the merits the substantive claim to which such remedy
relates).

 

    	 	11	 

    	 

    

 

(j) Submission
to Jurisdiction. The Parties agree that any Action seeking to enforce any provision of, or based on any matter arising out
of or in connection with, this Agreement or the transactions contemplated hereby (whether brought by any party or any of its Affiliates
or against any party or any of its Affiliates) shall be brought in the state or federal courts, as applicable, in New York county
in the State of New York, and each of the Parties irrevocably consents to the exclusive jurisdiction of such courts (and of the
appropriate appellate courts therefrom) in any such Action and irrevocably waives, to the fullest extent permitted by Law, any
objection that you may now or hereafter have to the laying of the venue of any such Action in any such court or that any such
Action brought in any such court has been brought in an inconvenient forum. Process in any such Action may be served on any Party
anywhere in the world, whether within or without the jurisdiction of any such court. Without limiting the foregoing, each party
agrees that service of process on such party as provided in Section 10(d) shall be deemed effective service of process
on such party.

 

(k) Waiver
of Jury Trial. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING
ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY.

 

(l) Waiver.
Any term or condition of this Agreement may be waived at any time by the party that is entitled to the benefit thereof, but no
such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the party waiving such
term or condition, and no waiver by any party of any default, misrepresentation, or breach of warranty or covenant hereunder,
shall be deemed to extend to any prior or subsequent default, misrepresentation, or breach of warranty, covenant or agreement
hereunder or affect in any way any rights arising by virtue of any such prior or subsequent occurrence. No failure or delay of
any party in exercising any right or remedy hereunder shall operate as a waiver thereof, and no waiver by any party of any term
or condition of this Agreement, in any one or more instances, shall be deemed to be or construed as a waiver of the same or any
other term or condition of this Agreement on any future occasion.

 

(m) Counterparts;
Facsimile Signature. This Agreement may be executed in one or more counterparts, by original or facsimile (or other such electronically
transmitted) signature, each of which will be deemed an original, but all of which will constitute one and the same instrument.
A party executing this Agreement by facsimile (or other such electronically transmitted) signature shall, upon request from the
other party, promptly deliver to the requesting party an original counterpart of such signature.

 

    	 	12	 

    	 

    

 

(n) Rights
Cumulative. All rights and remedies of each of the parties under this Agreement will be cumulative, and the exercise of one
or more rights or remedies will not preclude the exercise of any other right or remedy available under this Agreement or Applicable
Law.

 

(o) Interpretation.
(a) The words “hereof”, “herein”, and “hereunder” and words of similar import, when used in
this Agreement, shall refer to this Agreement as a whole and not to any particular provision of this Agreement; (b) the words
“date hereof,” when used in this Agreement, shall refer to the date set forth in the Preamble; (c) the terms defined
in the singular have a comparable meaning when used in the plural, and vice versa; (d) the terms defined in the present tense
have a comparable meaning when used in the past tense, and vice versa; (e) any references herein to a specific Section or Article
shall refer, respectively, to Sections or Articles of this Agreement; (f) wherever the word “include”, “includes”,
or “including” is used in this Agreement, it shall be deemed to be followed by the words “without limitation”;
(g) references herein to any gender include each other gender; (h) the word “or” shall not be exclusive; (i) the headings
herein are for convenience of reference only, do not constitute part of this Agreement and shall not be deemed to limit or otherwise
affect any of the provisions hereof; (j) any references herein to any Governmental Authority shall be deemed to also be a reference
to any successor Governmental Authority thereto; and (k) the parties hereto have participated jointly in the negotiation and drafting
of this Agreement and, in the event that an ambiguity or question of intent or interpretation arises, this Agreement shall be
construed as jointly drafted by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any
party by virtue of the authorship of any provision of this Agreement.

 

(p) Effectiveness.
This Agreement shall become effective as of the Closing. Notwithstanding the preceding sentence, this Section 10 shall
survive any termination of this Agreement.

 

[Signature
page to follow]

 

    	 	13	 

    	 

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first written above.

 

	COMPANY:
	 
	 	 
	ONCOSEC
    MEDICAL INCORPORATED	 
	 	 
	
By:	/s/
    Daniel J. O’Connor	 
	Name:	Daniel J. O’Connor	 
	Title:	Chief Executive
    Officer and President	 
	 	 	 
	BUYER:	 
	 	 
	GRAND
    DECADE DEVELOPMENTS LIMITED	 
	 	 
	By:	/s/
    Zhou Chao	 
	Name: 	Zhou Chao	 
	Title:	Authorized Representative	 

 

[Signature
Page to Stockholders Agreement]

 

    	 	14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}]]